Deal Statistics Quarterly, Q3 2000
Executive Summary
In Vivo presents the second installment of a new quarterly feature--a statistical review compiled from Windhover's Strategic Transactions Database of the deal activity within the pharmaceuticals, biotechnology, medical device and in vitro diagnostics industries.
You may also be interested in...
Medtronic Addresses Diabetes Care Disparities With New Equity Initiatives
The company announced new research investments and partnerships with the American Diabetes Association and the T1D Exchange to address racial disparities in treatment of diabetes.
QUOTED. 19 April 2021. Jeff Shuren & William Maisel
Two top officials in the US FDA’s device center are warning of delays in the agency’s review of submissions for new products that aren’t directly tied to the coronavirus pandemic.
Breakthrough Therapy Designations At US FDA Stay Sluggish In 2021
With 12 new BTDs announced so far this year, 2021 is on pace to match the COVID-19-depressed total number of designations in 2020. Here’s a breakdown of the candidates that have received the designation.